Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Mektovi (binimetinib) is an oral MEK inhibitor used together with Braftovi (encorafenib) to treat BRAF-mutant cancers, offering greater anti-tumor activity and delayed resistance compared to either drug alone.
Mektovi, combined with Braftovi, is FDA-approved for adults with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, and for adults with metastatic non-small cell lung cancer with a BRAF V600E mutation.
Binimetinib inhibits MEK1/MEK2, blocking the MAPK signaling pathway downstream of mutated BRAF, which halts tumor cell growth when combined with the BRAF inhibitor encorafenib.
The recommended dose is 45 mg orally twice daily, combined with encorafenib, continued until disease progression or unacceptable toxicity, as determined by the treating oncologist.
Mektovi, used in combination with Braftovi, requires monitoring for several important safety considerations.
Including pulmonary embolism, has been reported. Monitor for signs of blood clots.
Monitor for new or progressive unexplained pulmonary symptoms.
Monitor liver function tests before starting, monthly during treatment, and as clinically indicated.
Assess left ventricular ejection fraction before starting and periodically during treatment.
Retinal vein occlusion and other eye disorders can occur. Perform ophthalmologic exams for visual disturbances.
Mektovi can cause fetal harm. Effective contraception is required during treatment and for a defined period after the final dose.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Mektovi (binimetinib) is manufactured by Pfizer and is used together with Braftovi (encorafenib) for BRAF-mutant melanoma and NSCLC.
Import of Mektovi through a Named Patient Program requires a valid prescription from the treating oncologist, confirmation of BRAF mutation status via an FDA-approved test, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Mektovi directly from Pfizer's authorized supply chain to ensure product authenticity and regulatory compliance.
Mektovi is sourced through verified, GDP-compliant channels from Pfizer's authorized supply chain to ensure authenticity and quality.
Mektovi tablets should be stored at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F).
Once sourced, Mektovi is packed and transported under appropriate temperature-controlled conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Mektovi through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading oncology centers in Mumbai support BRAF mutation testing and treatment coordination for Mektovi access.
Delhi's major cancer hospitals assist patients with molecular testing and prescription support for Mektovi.
Bangalore's oncology network offers access to BRAF testing and treatment planning for eligible patients.
Chennai-based specialists coordinate Mektovi access alongside comprehensive melanoma and lung cancer care.
Hyderabad's cancer care institutions support patients pursuing Mektovi therapy following confirmed BRAF mutation status.
Kolkata's oncology centers help coordinate documentation and treatment access for Mektovi.
Pune-based oncologists assist with BRAF mutation testing and Mektovi treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Mektovi.
Kochi's oncology units assist patients with the documentation needed for Mektovi access.
Chandigarh's cancer care centers support Mektovi treatment coordination for patients from North India.
Jaipur's oncology specialists help patients navigate the Mektovi access process.
Lucknow-based cancer centers assist patients pursuing Mektovi therapy.
Bhubaneswar's oncology institutions support access to Mektovi for eligible patients.
Guwahati's specialists help coordinate Mektovi access for patients across the Northeast.
Patients in other cities across India can also access Mektovi through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
